A Phase 3 interventional study of Lemborexant and Placebo in Epilepsy and Sleep, sponsored by University of Manitoba. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-13.
Sponsored by University of Manitoba · Phase 3, Interventional, and Treatment
The goal of this clinical trial is to assess whether Lemborexant can improve sleep in patients with epilepsy.
1,805 studies on the registry are indexed under Epilepsy; 417 are open to participants now.
This study's planned enrollment of 26 is below the median of 50 across 1,206 interventional studies indexed under Epilepsy.
Browse Epilepsy studies →University of Manitoba is the lead sponsor of 542 studies on the registry; 87 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 5 (42%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
0mg
Drug: Lemborexant · Drug: Placebo
10mg qhs
Drug: Lemborexant · Drug: Placebo
Drug is administered
Also known as: Dayvigo
Drug is administered
WASO
Wake After Sleep Onset (recorded using PSG)
Time frame: 36 Days
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Manitoba